MD Medical Group IPJSC (“MD Medical”, "Group" or the "Company"; MOEX: MDMG), a leading Russian private healthcare provider, announces its operating and unaudited financial results for Q3 and 9M2026.

Key financial highlights for Q3 2026:

• The Group's total revenue grew by 24.1% to reach RUB 14,404 million due to robust growth in out-patient and in-patient services, including the contribution from the Group's newly acquired assets – Ilyinskaya Hospital and the Zdravitsa out-patient network – as well as traditionally strong performance in delivery services;

• The Group's like-for-like (LFL) revenue increased by 13.2% y-o-y to reach RUB 13,131 million;

• Revenue of Moscow hospitals went up by 33.4% y-o-y to RUB 6,426 million, primarily due to growth in in-patient care revenue in oncology and surgery, as well as out-patient care revenue, which was partly driven by the consolidation of Ilyinskaya Hospital's results, along with strong performance in delivery services;

• Revenue of the Group's regional hospitals increased by 11.6% y-o-y to RUB 3,460 million, driven by strong revenue growth in delivery services, in-patient care in obstetrics and gynaecology, traumatology, and surgery, as well as services provided by treatment and diagnostic centres;

• Revenue of the Group's out-patient clinics in Moscow and the Moscow Region rose by 17% y-o-y to RUB 1,214 million, mainly as a result of higher revenue, especially IVF-generated, as well as out-patient visits;

• Revenue of the Group's out-patient clinics in other regions went up by 24.7% y-o-y to RUB 3,275 million, primarily driven by strong revenue growth associated with out-patient visits, which was partly due to the consolidation of the Zdravitsa clinic network's results as well as IVF revenue dynamics;

• The Group's net debt as of 30 September 2026 amounted to RUB 6,761 million, including RUB 3,757 million in lease liabilities[1];

• Capex in Q3 2026 was RUB 877 million.

Key operational highlights for Q3 2026:

• Total out-patient treatments increased by 5.8% y-o-y to 1,431,293, with the average ticket up 13.1% y-o-y to RUB 8 thousand in Moscow and up 15.8% y-o-y to RUB 3 thousand in other regions.

• Total in-patient treatments increased by 9.3% y-o-y to 37,374, the number of surgeries grew 8%. The average in-patient care ticket up 25.1% y-o-y to RUB 159.8 thousand in Moscow and up 7.1% y-o-y to RUB 56.6 thousand in other regions.

• Total deliveries increased by 15.1% y-o-y to 4,054, with the average ticket up 4.1% y-o-y to RUB 682.7 thousand in Moscow and up 11.4% y-o-y to RUB 299.4 thousand in other regions.

• Total IVF punctures went up by 8.8% y-o-y to 5,838, with the average ticket up 4.4% to RUB 352.4 thousand in Moscow and up 6.4% y-o-y to RUB 346.2 thousand in other regions.

Key financial highlights for 9M 2026:

• The Group's total revenue increased by 27% y-o-y to RUB 39,213 million, largely propped by revenue growth in out-patient services and in-patient medical care partly due to the new assets consolidation as well as traditionally strong demand for delivery services;

• The Group's like-for-like (LFL) revenue rose by 11.9% y-o-y to RUB 34,547 million;

• Revenue of the Group's Moscow hospitals grew by 18.4% y-o-y to RUB 16,462 million due to higher revenue from in-patient medical care and strong performance in delivery services;

• Revenue of the Group's regional hospitals increased by 21.3% y-o-y to RUB 10,006 million thanks to revenue growth in out-patient services and in-patient care as well as traditionally strong demand for delivery services;

• Revenue of the Group's out-patient clinics in Moscow and the Moscow Region went up by 17.8% y-o-y to RUB 3,406 million, supported by revenue growth from both out-patient visits and IVF procedures;

• Revenue of the Group's out-patient clinics in other regions grew by 60.6% y-o-y to RUB 9,221 million, primarily due to the contribution of the newly acquired Expert and Zdravitsa clinics in terms of out-patient visit dynamics, as well as strong IVF results;

• Total Capex for 9M 2026 amounted to RUB 3,453 million.

Key operational highlights for 9M 2026:

• Total out-patient treatments increased by 40.9% y-o-y to 4,123,471, with the average ticket up 12.4% y-o-y to RUB 7.7 thousand in Moscow and up 11.9% y-o-y to RUB 2.9 thousand in other regions.

• Total in-patient treatments increased by 2.5% y-o-y to 109,465, the number of surgeries grew 20.7% that inter alia caused the average in-patient care ticket up 12.5% y-o-y to RUB 141.3 thousand in Moscow and up 11.1% y-o-y to RUB 55.8 thousand in other regions.

• Total deliveries increased by 13.4% y-o-y to 10,755, with the average ticket up 5% y-o-y to RUB 670.6 thousand in Moscow and up 15.6% y-o-y to RUB 295.8 thousand in other regions.

• Total IVF punctures went up by 3.6% y-o-y to 16,432, with the average ticket up 10.6% to RUB 363 thousand in Moscow and up 9% y-o-y to RUB 341 thousand in other regions.

Key events during Q3 2026 and after the reporting period:

H1 2026 Dividends announcement. At the meeting held on 30 September 2026, the Company’s Board of Directors decided to distribute dividends for 6M 2026 in the amount of RUB 2,855 million, or RUB 38 per ordinary share, representing a payout of 54% of the Group's IFRS consolidated net profit for 6M 2026.

Expansion of the clinic in Moscow. On 8 July 2026 one of the first clinics of the Group, Mother&Child Ugo-Zapad multifunctional family center has now moved to a spacious several-storey building covering an area of 1,077 sq m, which is 276 sq. m. more than the previously occupied premises. The clinic's capacity allows for 78,000 patient appointments per year, which is 12,000 more than the previous capacity, and 1,600 IVF punctures per year. Investments in the clinic expansion amounted to RUB 162 mln.

MD Medical CEO Mark Kurtser said:

"I am pleased to present the Group’s results for Q3 2026. Revenue grew by 24% in Q3 2026 and by 27% in 9M 2026. This is a natural outcome of two complementary processes: our organic growth and successful integration of new assets.

The primary growth drivers were our out-patient and in-patient segments. This momentum was further strengthened by new additions to the Group – Ilyinsky Hospital and the Zdravitsa out-patient network – which contributed to the revenue growth of both Moscow hospitals and regional clinics. The integration of Ilyinsky Hospital has noticeably impacted the structure of our service portfolio, with the share of complex and high-tech cases increasing, which is reflected in the positive trend in the average ticket.

Importantly, like-for-like (LFL) revenue, excluding new assets, is also growing at double-digit rates. The Group’s growth is underpinned by steady demand for our services across all regions of our presence.

A key highlight is childbirth services. The continued growth in the number of deliveries is a source of particular pride for us: the birth of a child remains at the heart of our Company, just as it was at our inception. In Q3 2026, the number of deliveries in Moscow hospitals increased by 18%. Lapino-4 Hospital made a significant contribution: in its first year of operation, it achieved delivery volumes that exceeded our own expectations. The number of deliveries in our hospitals in other regions grew by 13%, with the St Petersburg hospital continuing to demonstrate traditionally high figures.

The quarter's results confirm the soundness of our strategy: we continue to invest in the development of our network and integrate new assets, and we are confident that this will create additional value for our patients and shareholders."

---

[1] According to IFRS 16, lease liabilities are recognised as debt.

***

Notes:
1.     Data is based on management accounts
2.     Minor variations in calculation of totals, subtotals and/or percentage change are due to rounding of decimals



About MD Medical Group

MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. Today, the Company manages 97 state-of-the-art healthcare facilities, including 15 multidisciplinary hospitals and 82 out-patient clinics in 35 regions of the Russian Federation. In 2025, MD Medical Group's revenue amounted to RUB 43.5 bln. while EBITDA stood at RUB 13.3 bln. The Company's ordinary shares are traded on Moscow Exchange (MOEX: MDMG).